Asthma has been recognised as a respiratory disorder for millennia and the focus of
targeted drug development for the last 120 years. Asthma is one of the most common …

History suggests β agonists, the cognate ligand of the β 2 adrenoceptor, have been used as
bronchodilators for around 5,000 years, and β agonists remain today the frontline treatment …

Acc. to history, β-agonists, the cognate ligand of the 2 adrenoreceptor, have been used as
bronchodilators for around 5,000 years, and they are still the first-line treatment for asthma …

It is time to end our love affair with short-acting β2-agonists in asthma | European
Respiratory Society Skip to main content Main menu Home Current issue Early View …

The discovery of adrenergic agonists and corticosteroids at the start of the 20th century has
provided the basis for much of the treatment of asthma. The last 50 years has witnessed …

The long-acting beta-2-agonists have become indispensible in modern asthma therapy. But
do they have a fixed position in international guidelines? Here are the proceedings of the …

The introduction of long-acting b2-adrenergic agonists (salmeterol and formoterol) in the
early 1990s came at a rather critical moment. Various epidemiological studies had recently …

This book provides a state-of-the-art account by academic respiratory physicians and senior
pharmaceutical industry personnel on the development of new drugs for asthma, allergy and …

Currently available therapy for asthma is highly effective and is able to control the majority of
patients so that they can lead a normal life. National and international guidelines for the …

A cardinal diagnostic feature of asthma is the marked improvement in spirometric values that
rapidly follows the aerosol administration of a; 3-adrenergic drug. The equally evident …